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Abstract: The usefulness of polyunsaturated fatty acids on inflammatory, cardiovascular, and the
nervous system was studied in the last decades, but the mechanisms underlying their benefic
properties are still partially unknown. These agents seem to express their action on the membrane
phospholipid composition and permeability and modulation of second messenger cascades. In
psychiatry, the efficacy and tolerability of omega-3 fatty acids were investigated in several psychiatric
disorders, including major depression, bipolar disorder, personality disorders, high-risk conditions to
develop psychosis, attention-deficit hyperactivity disorder, and autism spectrum disorders. Initial
findings in this field are promising, and some relevant questions need to be addressed. In particular, the
effects of these agents on the main symptom dimensions have to be investigated in a trans-diagnostic
perspective. The present systematic review is aimed to examine the available data on the efficacy
of omega-3 fatty acids on domains of psychotic symptoms, affective symptoms, impulsivity, and
aggressiveness, and harmful behaviors, and suicide risk.
Keywords: omega-3 fatty acids; PUFAs; psychiatric disorders; psychosis; affectivity; impulsivity;
self-harm behaviors
1. Introduction
In the last decades, the scientific literature has highlighted an urgent need to identify new
compounds to treat psychiatric disorders in order to improve and boost available medications that entail
not insignificant side effects. [1] As the harmful effects of the western diet, the absence of polyunsaturated
fatty acids (PUFAs), on immune memory and inflammation processes are recognized [2], several
studies evaluated the relationships between the low plasma level of long-chain polyunsaturated fatty
acids and several medical conditions. [3] The effects of omega-3 fatty acids (n-3 PUFAs), including
α-linolenic acid (ALA), eicosapentaenoic acid (EPA), and docosahexaenoic acid (DHA), and of omega-6
fatty acids (n-6 PUFAs), including linoleic and arachidonic acid on overall human health have been
extensively studied [4–6].
Nowadays, a consistent body of literature supports the importance of polyunsaturated fatty
acids in brain function and the effect of their supplementation in mental disorders, but the molecular
mechanisms underpinning their action are not completely clear [7–9]. Omega-3 fatty acids are essential
fatty acids that humans and other animals require for good health, but cannot be synthesized. So, these
compounds are introduced into the organism with food and metabolic conversion. The lipid derivatives
of omega-3 PUFAs include anti-inflammatory eicosanoids, such as resins and resolvins, which mediate
the effects on immune function [10,11]. Long-chain PUFAs, including at least 20 carbon atoms, have
important functional roles as components of phospholipids forming the cell membranes [12], and as
signaling molecules in all tissues, including the brain [13,14]. DHA is an essential omega-3 long-chain
Int. J. Mol. Sci. 2020, 21, 6042; doi:10.3390/ijms21176042 www.mdpi.com/journal/ijms
Int. J. Mol. Sci. 2020, 21, 6042 2 of 27
polyunsaturated fatty acid involved in many cellular processes in mammalian cells [15], represents
approximately 60% of PUFAs in neuronal membranes [16], and is a precursor for bioactive compounds
that modulate cell signaling and gene expression [17]. It takes part in neuronal growth, development,
and function, acting as a neurotrophic factor and modulating synaptic activity [18], and it has been
found to reduce the deleterious effects of chronic activation of inflammatory signaling cascades in the
brain and to ameliorate neurotoxic injuries implicated in neurodegenerative disorders [19].
Some investigations showed that cellular molecules such as resolvins, protectins, peroxisome
proliferator-activated receptor γ (PPAR-γ), AMP-activated protein kinase (AMPK), and nuclear factor
kappa-light-chain-enhancer of activated B cells (NF-κB) are potential targets of the anti-inflammatory
action of DHA [20–22]. Other authors observed that DHA supplementation in an aged rat model could
reduce cerebral reactive oxygen species, prevent age-related cognitive dysfunction [23], and decrease
oxidative stress in rats subjected to permanent cerebral ischemia [20]. Another potential mechanism of
the action of DHA is the regulation of the retinoid X receptor (RXR) that is a crucial developmental and
survival factor implicated in multiple transcription pathways, such as the dopaminergic system [24].
Supplementation with uridine, DHA, and choline resulted in enhanced levels of
phosphatidylcholine (PC), as well as other membrane phospholipids in the brains of healthy adult
rodents [25]. The same effect was observed when DHA was substituted with EPA, but not with
the omega-6 PUFA arachidonic acid (AA) [26]. The combination of DHA and EPA also intensified
membrane phospholipid levels in brains of pups born from rats supplemented during gestation and
nursing and produced an increased number of dendritic spines per unit area and the improvement
of synaptic activities [25,27]. These findings suggested that synaptogenesis is partially determined
by the availability of phospholipid precursors into the brain. In fact, phospholipid precursors
supplementation in animal models produced biochemical and structural modifications promoting
the release of neurotransmitters, such as dopamine [28] and acetylcholine [29], and improvement in
specific cognitive tasks [30].
Supplementation with phospholipid precursors not only enhanced synaptogenesis in normal
conditions, but also provided benefit under degenerative conditions that are characterized by synaptic
deficiency both in laboratory rodents and humans. The restorative effects of supplementation with
uridine monophosphate (UMP), DHA, and choline were indicated by increasing striatal dopamine
levels and tyrosine hydroxylase (TH) activity, and by enhancing levels of membrane phospholipids
and synaptic proteins in a rat model of Parkinson’s disease [31].
On the basis of these preclinical findings [32], several studies have been performed to test the
usefulness of these agents in clinical conditions. Recent reviews [7–10] and meta-analyses [33,34]
supported the role of PUFAs in the treatment of psychiatric disorders. In particular, the efficacy
and tolerability of omega-3 fatty acids (DHA and EPA) were investigated in major depression,
bipolar disorder, personality disorders, high-risk conditions to develop psychosis, attention-deficit
hyperactivity disorder, and autism spectrum disorders. An interesting perspective is to deal with
the effects of these agents in a trans-diagnostic perspective and investigate their effects on the main
psychiatric symptom dimensions. The present systematic review is aimed to examine available data on
the efficacy of omega-3 fatty acids on domains of psychotic symptoms, affective symptoms, impulsivity,
and harmful behaviors.
2. Psychotic Symptoms
Deficits in long-chain n-3 PUFAs are one of the mechanisms thought to contribute to the risk of
psychosis [35]. In schizophrenia and other psychotic disorders, the phospholipid structure of the cell
membrane is altered and these modifications may contribute to various features of the pathophysiology
observed in psychotic disorders, including neurotransmission, immune activation, and antioxidative
defense [36]. This hypothesis is supported by studies that showed a plasma n-3 PUFAs deficiency in
patients with schizophrenia compared to controls. [37] Besides, some evidence has suggested that
the onset of psychotic disorders arises during human brain development in which n-3 PUFAs play
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a central role [38]. So, n-3 PUFAs supplementation could have an effect in preventing transition to
psychosis [39,40], in particular, in high-risk populations [41].
These initial promising findings allow us to take into consideration the use of non-pharmacological
compounds for early interventions in young people at risk for psychosis [42]. The results obtained
so far about PUFAs as an add-on strategy in the treatment of schizophrenia are controversial; while
several studies [40–57] produced favorable data, some others [58–61] showed no significant differences
in clinical outcomes.
The symptoms dimension of psychosis is characterized by abnormalities in five symptom domains:
delusions, hallucinations, disorganized thinking, disorganized behaviors, and negative symptoms.
Lower levels of n-3 PUFAs seem to correlate with more severe negative symptoms in ultra-high risk
(UHR) patients for psychosis and could be adopted as a biomarker that predicts the conversion to
psychosis in UHR subjects [43].
Some findings suggested a role of EPA as an add-on therapy (in combination with antipsychotic
therapy) in general, positive, negative, and depressive symptoms [46,47,49–51] in patients with UHR
and first episode of psychosis. EPA or DHA augmentation to antipsychotics reduced the deterioration
of hippocampus tissues with a positive effect on negative symptoms [47], decreased the oxidative
stress status of plasma with a positive effect on global and negative symptoms [50], and increased the
telomerase levels in peripheral blood cells with a positive effect on the severity of illness [51].
Some authors suggested that in stable schizophrenia, omega-3 fatty acid supplementation had a
beneficial effect on positive symptoms (delusions and hallucinations) [52,55]. Among PUFAs, EPA
has been found superior than placebo and also than DHA in reducing positive [52,55] and negative
symptoms [54]. Moreover, supplementation with EPA induced a less severe impairment of the course
of psychosis [56].
Previous findings [62] showed that omega-3 fatty acids have beneficial effects on triglycerides
in patients with psychotic symptoms and metabolic syndrome and may enhance the brain-derived
neurotrophic factor (BDNF) levels through their anti-inflammatory properties with a reduction of
cognitive dysfunction in these patients [63]. Probably, an appropriate dietary supplementation could
play a partially therapeutic effect even in more severe patients, improving some behavioral aspects
and reducing the cognitive deterioration [64]. In addition, EPA supplementation was found to be
associated with a marked increase of glutathione, an antioxidant agent, in patients with first episode of
psychosis. [46]
Further studies are needed to investigate the role of omega-3 fatty acids as a treatment for the
specific clusters of psychotic symptoms in psychiatric disorders other than schizophrenia. In fact, there
is lack of evidence regarding the efficacy of PUFAs on the psychotic cluster of symptoms in bipolar
disorder, schizoaffective disorder, and schizotypal personality disorder. To our knowledge only one
case report documented the benefits of omega-3 fatty acids supplementation (EPA 1.187 g/day + DHA
0.613 g/day) in association with cholecalciferol (vitamin D3) and mood stabilizers for psychotic features
in bipolar disorder [65].
In apparent contrast with the expectations, higher scores on positive schizotypal trait measures in
healthy adults were found to be associated with higher concentrations of omega-6 and omega-3 fatty
acids in red cell membranes [66]. These findings seem to support the hypothesis that high blood levels
of PUFAs may confer some protection against psychotic breakdown [67].
Main findings are displayed in Table 1.
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Table 1. Randomized controlled trials and open trials of omega-3 PUFAs on psychotic symptoms.
Study (Year) [Ref.] Interventional Arm(s) Comparison Arm(s) Sample Treatment Duration Results
Amminger et al., 2013 [40]
EPA
700 mg/day + DHA
480 mg/day +






↓ positive symptoms, negative
symptoms and
general symptoms,
↑ level of functioning
Amminger et al., 2015 [42]
EPA






6.7 years follow-up ↓ risk of progression to psychoticdisorder and psychiatric morbidity





Placebo 81 individuals at UHR 12 weeks














normalizing PLA2 activity and
d-6-desaturase-mediated








antipsychotics 69 patients at FEP 12 weeks accelerated treatment response
Berger et al., 2008 [46] EPA 2 g/day +Antipsychotics
Placebo +
antipsychotics 24 patients at FEP 12 weeks ↓ of negative symptoms





antipsychotics 17 patients at FEP 12 weeks
increased water in hippocampal
tissues and
positive effect on negative
symptoms
Emsley et al., 2014 [48] EPA 2 g/day + DHA 1g/day + α-LA 300 mg/day placebo
33 patients after FEP on
antipsychotic
discontinuation
2 years relapse prevention of psychoticsymptoms
Pawelzcyk et al., 2016 [49] EPA + DHA2.2 g/day Placebo 71 patients at FEP 26 weeks
↓ psychotic symptoms measured
with PANSS
↓ depressive symptoms
↑ level of functioning
Pawelzcyk et al., 2017 [50] EPA + DHA2.2 g/day placebo 71 patients at FEP 26 weeks
improved PANSS negative and
general
symptoms, along with global
functioning
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Table 1. Cont.
Study (Year) [Ref.] Interventional Arm(s) Comparison Arm(s) Sample Treatment Duration Results






45 patients with stable
schizophrenia 12 weeks
↓ psychotic symptoms measured
with PANSS in
the group treated with EPA






115 patients with stable
schizophrenia 12 weeks





















60 patients with stable
schizophrenia 8 weeks
↓ psychotic symptoms measured
with PANSS






99 patients with stable
schizophrenia 16 weeks
↓ impairment of the course of
psychosis
Robinson et al., 2019 [57]




Antipsychotics 50 patients with stable
schizophrenia 16 weeks
↓ confusion, anxiety, depression,
irritability and
tiredness/fatigue




Placebo + antipsychotics 77 patients with stableschizophrenia 12 weeks
no efficacy on specific psychotic
symptoms






87 patients with stable
schizophrenia 16 weeks
no significant differences in
positive, negative
symptoms, mood or cognition
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3. Affective Symptoms
Affective symptoms include depression, hypomania, mania, and anxiety symptoms. Abnormalities
in affectivity characterize mood disorders but are also frequently associated with other mental disorders,
such as psychotic and personality disorders. The role of PUFAs in treating affective symptoms such as
depression can be linked to the inflammation hypothesis of the pathogenesis of depression and to the
effects of EPA and DHA in reducing the effects of chronic activation of the inflammatory cascade [68].
In addition, it has been found that patients with major depressive disorder (MDD) have a lower level of
EPA and DHA in their peripheral tissues (plasma, serum, and red blood cells) than control subjects [69].
The antidepressant efficacy of PUFAs could be partly explained by their role in myelinization
processes—several models have been proposed to explain oligodendroglia cell loss/dysfunction in MDD.
Increased levels of circulating corticosterone linked to the over-activation of the hypothalamic, pituitary,
adrenal (HPA) axis in stress conditions could be at the origin of oligodendroglia loss/dysfunction
in depression [70]. Studies in rats show that lower omega-3 PUFAs intake causes abnormalities of
myelin [71] and that omega-3 PUFAs administration stimulates the expression of myelin proteins
through the activation of signaling pathways involved in brain development [72]. Some experimental
brain injury studies in rodents support this association and conclude that the supplementation with
n-3 PUFAs increases the degree of differentiation of oligodendroglia cells [73,74].
Furthermore, an unbalanced omega-3/omega-6 ratio could lead to a range of functional
consequences in the monoamine transport system [75]. In fact, there is evidence that severe n-3
PUFA deficiency alters the dopaminergic and serotonergic transmission systems, inducing an increased
vulnerability to mood disorders. The mesolimbic dopaminergic pathway was more active, whereas
the mesocortical pathway was found to be less active in rats with n-3 PUFA deficiency. This imbalance
in dopaminergic neurotransmission could be related to symptoms of depressive episodes, such as lack
of motivation, decreased response to reward, and impairment in intellective abilities [76].
The inflammatory response and the stimulation of BDNF have been hypothesized as two potential
mechanisms through which omega-3 fatty acids could provide their anxiolytic effect. In particular,
as anxiety is associated with an increased production of pro-inflammatory cytokines, including
tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), the effect of n-3 PUFAs of decreasing
inflammatory cytokines indirectly promote the reduction of anxious symptoms. Moreover, when
BDNF is low, it fails to stimulate synaptic growth of serotonergic neurons in the brain, and low levels of
serotonin are associated with anxiety. Thus, BDNF could reduce depression and anxiety by stimulating
synaptic growth of serotonergic neurons in the brain [77,78].
A consistent number of studies [79–112] investigated the role of PUFAs in the treatment of
major depressive disorder (MDD). Although some of them [79–96] found no significant data, several
trials [97–112] showed an improvement of depressive symptoms in patients treated with n-3 PUFAs in
combination with antidepressants. In particular, a combination of higher dose of EPA with lower dose
of DHA (EPA 1.67 g/day + DHA 0.83 g/day), added to existing antidepressant treatment, revealed
beneficial effects on mood [102,103]. On the contrary, lower doses of EPA with higher doses of DHA
(EPA 0.6 g/day + DHA 2.2 g/day added to standard therapy) evidenced no benefits on depressive
symptoms [85]. Some authors [108] stated that higher doses of n-3 PUFAs (EPA 2.1/day + DHA
2.5 g/day) are more efficacious on depressive symptoms [85,86]. Several studies [113–120] investigating
the efficacy of n-3 PUFAs supplementation (2.5 g/day with EPA:DHA = 2:1) in patients who suffer
from bipolar disorder treated with mood stabilizers confirmed the effect of these agents on depressive
symptoms [120] but not on manic ones [8,9]. Unlike major depression, in the case of bipolar disorder,
higher doses of EPA (4.4 g/day) and DHA (2.4 g/day) seem to be not useful to obtain a better
improvement of affective symptoms [113]. The reviews [121–124] and meta-analyses [33,125] on this
topic concluded that there is a pressing need for further investigations, especially concerning the
manic symptoms.
With regard to anxious symptoms, observational and experimental studies have demonstrated
thatω-3 supplementation could ameliorate anxiety symptoms. Highω-3 fatty acid intake is associated
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with reduced likelihood of meeting the diagnostic criteria for anxiety disorders [126,127] and lower
levels of self-reported anxiety symptom severity [128,129]. However, the literature data on the efficacy
of PUFAs on anxiety are still scarce and inconclusive. Two trials [130,131] suggested a positive effect of
n-3 PUFAs (EPA 2.25 g/day + DHA 0.5 g/day) on anxiety in patients with substance abuse and one
open-label study reported an improvement of anxious symptoms in patients with post-traumatic stress
disorder [132].
Depressive and anxious symptoms often occur in patients with schizophrenia or other psychotic
disorders. In particular, young people at UHR to develop psychosis who present affective symptoms
(depression and anxiety) show lower plasma levels of omega-3 fatty acids and higher levels of omega-6
fatty acids then controls [41]. On this basis, some authors investigated the effects of EPA and DHA
supplementation in patients with schizophrenia and depressive and anxious symptoms. The results
showed that EPA at doses ranging between 1 and 4 g/day is efficacious in reducing the depressive
symptoms [50,54] and anxious symptoms [54] of schizophrenia. Among personality disorders, n-3
PUFAs were found efficacious on depressive symptoms of patients with borderline personality disorder
(BPD), both in monotherapy (EPA 1 g/day) [133] and in addition to standard pharmacotherapies (EPA
1.2 g/day + DHA 0.9 g/day) [134].
Main findings are displayed in Table 2.
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Table 2. Randomized controlled trials and open trials of omega-3 PUFAs on affective symptoms.
Study (Year) [Ref.] Interventional Arm(s) Comparison Arm(s) Sample Treatment Duration Results
Pawelzcyk et al., 2018 [51] EPA + DHA2.2 g/day placebo 71 patients at FEP 26 weeks
↑ level of telomerase in peripheral
blood cells
with ↓ depressive symptoms
Llorente et al., 2003 [79] DHA 0.2 g/day monotherapy Placebo 99 healthy pregnantwomen 16 weeks no effect on postpartum depression
Marangell et al., 2003 [80] add on to standard therapy DHA 2g/day monotherapy Standard therapy 36 patients with MDD 12 weeks no significant differences
Silvers et al., 2005 [81] EPA 0.6 g/day + DHA 2.4 g/dayadded to standard therapy Standard therapy 77 patients with MDD 12 weeks
no evidence that n-3PUFAs
improved mood
compared to placebo.
Mood improved in both groups
within the first 2 weeks
of the study
Greyner et al., 2007 [82] EPA 0.6 g/day + DHA 2.2 g/day addto standard therapy Standard therapy 83 patients with MDD 16 weeks no significant differences
Hallahan et al., 2007 [134] EPA (1.2 g/day) + DHA (0.9 g/day) Placebo 49 patients with self-harmbehaviors (35 BPD) 12 weeks
Improvement of depression,
suicidality and reaction to daily
stress
Freeman et al., 2008 [83] EPA 1.1 g/day + DHA 0.8 g/day placebo 59 women 8 weeks no benefit on perinatal depressivesymptoms
Jazayeri et al.,
2008 [84] EPA 1 g/day fluoxetine 20 mg/day 60 patients with MDD 8 weeks
↓ depressive symptoms in both
groups
Rees et al., 2008 [85] ethyl-EPA 0.4 g/day + DHA 1.6g/day placebo 26 pregnant patients 6 weeks
no benefits on depressive
symptoms
Rogers et al., 2008 [86] EPA 0.63 g/day + DHA 0.85 g/daymonotherapy placebo




n-3PUFAs not have beneficial or
harmful effects on mood in mild to
moderate depression.
Doornbos et al., 2009 [87]
DHA 0.22 g/day or DHA 0.22 g/day
+
AA (0.22 g/day arachidonic acid)
monotherapy
placebo 119 healthy pregnantwomen 28 weeks
red blood cell DHA, AA and
DHA/AA ratio did not correlate
with EPDS or blues scores
Lucas et al., 2009 [88] EPA 1.05 g/day + DHA 0.25 g/daymono-therapy placebo
120 patients with
psychological distress
with or without MDD in
comorbidity
8 weeks no significant differences
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Table 2. Cont.
Study (Year) [Ref.] Interventional Arm(s) Comparison Arm(s) Sample Treatment Duration Results
Makrides et al., 2010 [89]





women at 21 weeks’
gestation
women received assigned
capsules daily, from study
entry until birth of their
child
DHA during pregnancy did not
lower levels of
postpartum depression
Antypa et al., 2012 [90] EPA 1.74 g/day+ DHA 0.25 g/dayadded to standard therapy Standard therapy
71 patients with history of
at least one MDD 4 weeks
no significant effects on memory,
attention,
cognitive reactivity and depressive
symptoms
Mozurkewich et al., 2013
[91]
EPA 1.06 g/day+ DHA 0.27 g/day
monotherapy





no differences between groups in
BDI scores or
other depression endpoints
Mischoulon et al., 2009
[92]
EPA 1 g/day + (+ 0.2% dL
alphatocopherol) monotherapy placebo 57 patients with MDD 8 weeks
↓ depressive symptoms assessed
with HDRS, but no statistical
significance
Park et al., 2015 [93] EPA 1140 g/day + DHA 0.6 g/dayadd to standard therapy Standard therapy 35 patients with MDD 12 weeks no significant differences
Young et al., 2017 [94] PEP + EPA 1.4 g/day + DHA 0.2g/day + 0.4 g/day other placebo
72 depressed patients
7–14 years old 12 weeks
↓ co-occurring behavior symptoms
in youth with depression.
Gabbay et al., 2018 [95]
2:1 ratio of EPA to DHA: Initial
dose
of 1.2 g/day. Doses were raised in
increments of 0.6 g/day every 2
weeks
(maximum possible dose of






aged 12–19 years old
10 weeks n-3PUFAs do not appear to besuperior to placebo.




12 weeks no significant differences
Nemets et al., 2006 [97] ethyl-EPA 0.4 g/day + DHA 0.2g/day placebo 20 patients 6–12 years-old 16 weeks
↓ depressive symptoms measured
with CDRS, CDI and CGI
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Table 2. Cont.
Study (Year) [Ref.] Interventional Arm(s) Comparison Arm(s) Sample Treatment Duration Results
Peet & Horrobin 2002 [98] Ethyl-EPA 1/2/4 g/day + Standardtherapy
Placebo + Standard
therapy




Ethyl-EPA 1 g/day group > placebo
group
no significant differences in the
Ethyl-EPA 2 and 4 g/day groups
Su et al., 2003 [99]
ethyl-EPA






22 patients with MDD 8 weeks ↓ depressive symptomsmeasured with HDRS
Nemets et al., 2006 [100] ethyl-EPA0.4 g/day + DHA 0.2 g/day Placebo
20 depressed patients
6–12 years-old 16 weeks
↓ depressive symptoms measured
with CDRS, CDI and CGI
Mischoulon et al. (2009)
[101]
EPA 1 g/day + (+0.2% dL
alphatocopherol) monotherapy Placebo 57 MDD patients 8 weeks
↓ depressive symptoms assessed




EPA 1.67 g/day + DHA 0.83 g/day






residents in a nursing
home
8 weeks





Lespérance et al., 2011
[104]





432 patients with a major
depressive episode 8 weeks
↓ depressive symptoms only for




EPA 0.18 g/day + DHA 0.12 g/day
add to standard therapy (55
patients)
or in monotherapy (11 patients)
Placebo




low-dose n-3PUFAs have some
efficacy in mild to moderate
depression
Gertsik et al., 2012 [106]
EPA 0.9 g/day + DHA 0.2 g/day +










Krawczyk et al., 2012 [107]
EPA 2.2 g/day + DHA 0.7 g/day +
GLA (0.24 g/day) + vit. E added to
standard therapy
Standard therapy




8 weeks n-3PUFAs significantly improvedHDRS scores
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Table 2. Cont.
Study (Year) [Ref.] Interventional Arm(s) Comparison Arm(s) Sample Treatment Duration Results
Rizzo et al., 2012
[108]
EPA/DHA 2.1/2.5 g of n3-PUFA
monotherapy Placebo
46 MMD patients (only
women > 66 years old) 8 weeks
mean GDS score and AA/EPA ratio,
in whole










81 mild to moderate
depressed patients 12 weeks
↓ HDRS score EPA > compared
with those in the DHA or placebo
groups
Judge et al., 2014
[110] DHA 0.3 g/day Placebo
42 healthy pregnant
women 8 weeks
↓ depressive symptoms assessed
with PDSS
Ginty et al., 2015
[111]
EPA + DHA 1.4 g/day
monotherapy Placebo 23 depressed patients 3 weeks
n-3PUFAs group had a significant
reduction in
BDI scores over time
Jahangard et al., 2018
[112]




(50–200 mg/day) 50 MDD outpatients 12 weeks
↓ depression, anxiety, sleep and
patients’
competencies to regulate their
emotions.
Chiu et al., 2005
[113]
4.4 g/day
EPA + 2.4 g/day DHA added on
valproate 2 g/day
valproate 2 g/day and
16 newly hospitalized
patients in the acute
manic phase of bipolar
disorder





High dose: EPA, 5.0–5.2 g/day;
DHA, 3.0–3.4 g/day; other, 0.3–1.7
g/day + standard therapy
Standard therapy 21 patients with bipolardisorder 4 weeks No significant differences
Keck et al., 2006
[116]




121 patients with bipolar
depression or rapid
cycling bipolar disorder
4 months No significant differences
Frangou et al., 2006
[117]




75 patients with bipolar
disorder 12 weeks
↓ depressive symptoms measured
with HDRS
Murphy et al., 2012
[118]
omega-3 fatty acids plus cytidine or
omega-3 fatty acid plus placebo in
addition to a
mood stabilizer
only placebo in addition
to a
mood stabilizer
45 patients with type I
bipolar disorder 4 months
no benefits of omega-3 fatty acids
on affective
symptoms
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Table 2. Cont.
Study (Year) [Ref.] Interventional Arm(s) Comparison Arm(s) Sample Treatment Duration Results
Stoll et al., 1999
[119] EPA 6.2 g/day + DHA 3.4 g/day Placebo
30 patients with bipolar
disorder 16 weeks
↓ depressive symptoms measured
with HDRS
Gracious et al., 2010
[120]
ALA in addition to psychotropic
medication Standard therapy
children and adolescent
with bipolar I or II
disorder
16 weeks
significant improvement of overall





Ethyl-EPA 1 g/day (with no
standard
psychiatric therapies)





docosahexaenoic acid 3 g/day Placebo
44 patients with anxiety
disorder and substance
abuse disorder
3 months + 3 months after
therapy discontinuation
↓ anxiety symptoms > in PUFAs
group than in placebo one, also
after therapy discontinuation
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4. Impulsive and Aggressive Symptoms
There is cross-sectional evidence that deficiency of omega-3 fatty acids is associated with hostility,
aggressive behaviors, and impulsivity in both psychiatric and non-psychiatric populations [135]. The
relationship between omega-3 PUFAs and aggression have also been explored in rodent studies,
that have found an increase of aggressive behaviors with both omega-3 PUFAs deficiency [136] and
high-omega-6 PUFAs intake [137]. Omega-3 administration seems to have beneficial effects in reducing
aggression among the general population [138]. A study performed in a group of Australian inmates
found that the n-3 PUFAs levels were inversely related to the degree of aggressive behavior and
hostility [139]. The results of several studies collected in a meta-analysis [140] are encouraging for the
use of omega-3 fatty acid supplementation to prevent and reduce aggressive behaviors in both children
and adults. The relationship between abnormal PUFAs distribution and conditions characterized
by a high-level of impulsivity could be partly explained by the effect of these compounds on the
serotonin system and membrane stability. In particular, EPA influences serotonin release and DHA
improves membrane-embedded serotonin receptor accessibility with an increase of cognitive function,
propensity for prosocial behavior, and of impulsive behavior control [141].
Higher omega-6/omega-3 ratios have been found in subjects with anger, irritability, and
aggressiveness, in particular during exposure to elevated inflammatory cytokines [142]. Thus,
inflammation and inflammation-related genetic polymorphisms are two possible additional sources of
variability that may contribute to understanding the biological substrates of aggressive states [143].
The relationship between omega-3 PUFAs and aggressive and impulsive behaviors have been
observed in various psychiatric contexts. It is possible that omega-3 fatty acids may alter brain
functionality prior to emergent or detectable behavioral changes [135].
Lower plasma levels of total omega-3 PUFAs and a trend toward a higher ratio of omega-6 to
omega-3 PUFAs were observed in conditions with a high level of impulsivity. For example, among
subjects with gambling disorder, a higher percentage composition of EPA and a lower AA/EPA ratio
and AA/DHA ratio in the red blood cell membrane was observed in impulsive gamblers, compared
with non-impulsive ones [144]. In a similar way, cocaine abusers with impulsive and aggressive
behaviors showed an imbalance between omega-3 and omega-6 fatty acids [145,146], and violent males
and impulsive offenders hospitalized in a forensic psychiatric unit presented a lower plasmatic DHA
level than controls [147].
Some available evidence suggests a beneficial effect of omega-3 supplementation on aggressive
and antisocial behavior in adolescence and adulthood [148]. The mechanisms underpinning these
results is still unclear, although the upregulation of dysfunctional prefrontal regions is one candidate
mediator [149,150].
Studies that evaluated the effects of PUFAs on impulsivity and aggressiveness in major psychiatric
disorders indicated that the addition of rather low doses of omega-3 fatty acids (EPA 0.54 g/day + DHA
0.36 g/day) to antipsychotic treatment might reduce agitation and violent behaviors in inpatients with
schizophrenia in the chronic phase [61]. Single therapy with omega -3 fatty acids (EPA 0.93 g/day + DHA
0.29 g/day) showed an improvement of impulsive dyscontrol and aggressiveness in patients affected
by ADHD (attention deficit hyperactivity disorder) [151,152] and in patients affected by BPD [133,134].
Moreover, combined therapy with EPA (1–1.2 g/day) plus DHA (0.6–0.9 g/day) and valproic acid
(800–1300 mg/day—plasma range: 50–100 µg/mL) was superior to single therapy with valproic acid on
impulsive–behavioral dyscontrol and outbursts of anger in BPD patients [153]. Combined therapy
with omega-3 fatty acids showed long-lasting effects at the end of 24 weeks of follow-up in terms of
anger control [154].
Main findings are displayed in Table 3.
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Table 3. Randomized controlled trials and open trials of omega-3 PUFAs on impulsivity and aggression.
Study (Year) [Ref.] Interventional Arm(s) Comparison Arm(s) Sample Treatment Duration Results
Qiao et al., 2018 [61]





50 patients with stable
schizophrenia 12 weeks






Ethyl-EPA 1 g/day (with
no standard
psychiatric therapies)
placebo 30 females with BPD 8 weeks ↓ aggression
Ginty et al., 2017
[135]
EPA 1 g/day + DHA 0.4
g/day Placebo 272 healthy volunteers 18 weeks
No significative differences on impulsive





EPA 0.772 g/day +
DHA 0.638 g/day Placebo
194 Participants aged
18–45 from the general
population




EPA 93 mg/day + DHA 29
mg/day +
gamma-linolenic acid




(7 to 12 years)
with ADHD
15 weeks
improved in inattention, hyperactivity and
impulsivity in most ADHD scales in parents
reports; no improvement in teachers reports
Limits: No ADHD diagnosis (reported
ADHD symptoms)
Perera et al., 2012
[152]









improved behavior and learning in
restlessness,
aggressiveness, completing work and
academic
performance, but not in inattention,
impulsiveness and cooperation with parents
and
teachers
Bellino et al., 2014 [153]
EPA (1.2 g/day) + DHA
(0.8 g/day) + valproate
(800–1300 mg/day)
Valproate (800–1300
mg/day) 43 BPD outpatients 12 weeks
No differences with regard to global
symptoms. Improvement of impulsivity,
anger and self-mutilating conducts in
omega-3 group
Bozzatello et al., 2018
[154]
EPA (1.2 g/day) + DHA
(0.8 g/day) + valproate
(800–1300 mg/day)
Valproate (800–1300
mg/day) 43 BPD outpatients 24 weeks follow-up
Combined therapy with omega-3 fatty acids
showed long-lasting effects after
discontinuation in terms of anger control.
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5. Self-harm Behaviors and Suicidal Conducts
Self-harm behaviors include self-injuries, such as cutting and self-mutilation, burning, scratching,
or hitting body parts [155]. The desire to self-harm is a common symptom of some personality disorders,
but is frequent also in patients with mood disorders, anxiety disorders, substance use disorders, eating
disorders, post-traumatic stress disorder, and schizophrenia [156]. The classification challenge
presented by repetitive, non-lethal, self-harm is reflected in the numerous terms used for it in the
historical literature, including self-mutilation, focal suicide, parasuicide, suicide gesture, wrist-cutting
syndrome, delicate self-cutting, deliberate self-harm, self-injury, and self-injurious behavior. Currently,
DSM-5 [157] includes several types of repetitive, non-lethal self-injurious behaviors: nonsuicidal
self-injury (NSSI), trichotillomania (hair-pulling disorder), excoriation (skin-picking) disorder, and
suicidal behavior disorder.
A theoretical model indicates the pathways whereby cholesterol-lowering treatments could affect
PUFAs and lipid rafts, leading to alterations in serotonergic neurotransmission, corticotrophic function,
and inflammation, and thereby increase parasuicidal and suicidal risk. So, there could be a preventative
intervention, with respect to suicide and parasuicide, in administering n-3 PUFA supplements to
patients for whom lower cholesterol is medically important and who have or develop psychiatric
vulnerabilities, for example, patients with cardiac diseases or metabolic syndrome [158,159].
Unfortunately, studies on the effect of PUFAs on self-harm behaviors and suicide are still sparse.
Some of these were performed in subjects without a psychiatric diagnosis and showed that low n-3
PUFAs plasma levels were associated with an increased number of deaths for suicide compared with
other causes of death in active duty US military personnel. Moreover, veterans treated with PUFAs
reported a reduction in suicidal ideation after omega-3 fatty acid supplementation [160,161].
Other investigations found that low EPA and DHA percentages, elevated omega-6/omega-3 ratio,
and higher AA concentration seem to be associated with increased self-harm and suicidal attempts
in patients with mood disorders [162–165]. Having low levels of arachidonic acid and receiving a
combination of high dose of EPA and lithium were found protective for suicide attempts and deliberate
self-harm in the case of bipolar disorder [166].
In BPD patients, n-3 PUFAs supplementation (EPA 1–1.2 g/day + DHA 0.6–0.9 g/day), added
to standard psychiatric therapies, showed a significant reduction of self-harming and parasuicidal
attitudes [133,134,153,154]. In particular, the reduction of suicidal behaviors seems to be independent
of change in the depression score [134].
Main findings are displayed in Table 4.
Int. J. Mol. Sci. 2020, 21, 6042 16 of 27
Table 4. Randomized controlled trials and open trials of omega-3 PUFAs on self-harm behaviors.
Study (Year) [Ref.] Interventional Arm(s) Comparison Arm(s) Sample Treatment Duration Results
Hallahan et al., 2007 [134] EPA (1.2 g/day) + DHA (0.9 g/day) Placebo 49 patients with self-harmbehaviors (35 BPD) 12 weeks
Improvement of self-harm
behaviors, suicidality, and reaction
to daily stress
Bellino et al., 2014 [153] EPA (1.2 g/day) + DHA (0.8 g/day)
+ valproate (800–1300 mg/day)
Valproate (800–1300
mg/day) 43 BPD outpatients 12 weeks
No differences with regard to




Marriott et al., 2016
[160]
3300 mg of n-3 PUFAs/day with
1650 mg EPA plus 1650 mg DHA
per day
Placebo
40 United States (U.S.)
military Veterans and
non-Veterans ages 18–90
years with suicide risk
6 months ↓ suicidal behaviors
Gallagher et al., 2017
[165]
n-3 PUFAs including





↓ self-harm, ↓depressive symptoms
and
↓ impulsivity
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6. Conclusive Remarks
Recent evidence supports the importance of polyunsaturated fatty acids in brain functioning and
the action of their supplementation in psychiatric disorders, but the underlying mechanisms of the
potential preventive and therapeutic effect of PUFAs is still unclear.
Preclinical studies hypothesized that omega-3 fatty acids may attenuate stress-related changes
in animals with depressive features, as well as in humans [167]. These agents seem to be involved
in myelinization processes and synaptic pruning, that are fundamental processes during brain
development. PUFAs have immune-modulatory, and anti-inflammatory properties through the
modulation of omega-6 fatty acids and the promotion of resolvins, neuroprotective factors, and
anti-inflammatory mediators. They are also involved in membrane fluidity producing an improvement
of monoaminergic transmission.
In the last decades, the role of long-chain PUFAs in the treatment of several psychiatric disorders
has gradually increased, as confirmed by the growing number of randomized controlled trials testing
the efficacy of essential fatty acids, especially omega-3 supplementation. Nevertheless, an overall
agreement about their efficacy is still lacking, and the results of most trials are controversial and
inconclusive. Differences in methods, including sample size, selection criteria, choice, and dosage of
fatty acids (i.e., EPA, or DHA, or a combination of the two), and the duration of supplementation, often
make results not comparable.
The aim of this review is to evaluate, in a trans-diagnostic perspective, the efficacy of omega-3 fatty
acids on the main psychiatric symptom dimensions, in particular on domains of psychotic symptoms,
affective symptoms, impulsivity, and harmful behaviors.
Concerning psychosis, the available data on the effects of EPA and DHA needs to be replicated.
However, initial findings are rather promising and show that these compounds, in addition to
antipsychotics, may improve all symptom domains of psychosis, in particular negative symptoms.
Evidence on the effects of PUFAs as single therapy for schizophrenic patients and on psychotic
symptoms that are part of the clinical picture of psychiatric disorders other than schizophrenia are
not sufficient.
The available literature reported promising data also on the role of n-3 PUFAs in the treatment of
affective symptoms. In particular, these compounds, administered at high doses (1–2 g/day, with a ratio
EPA:DHA = 2:1), seem able to improve depressive symptoms, both in monotherapy and in addition to
antidepressants in major depression, in combination with mood stabilizers in bipolar depression, in
addition to antipsychotics in schizophrenia. Evidence of the efficacy of manic symptoms is lacking,
while the effects on anxiety need to be clarified and confirmed.
Concerning impulsivity and aggressiveness, the initial results on the beneficial effects of EPA
and DHA supplementation are encouraging, both in single and combined interventions, and induce
a decrease in the levels of impulsivity, outbursts of anger, and overt aggression. This area of
psychopathology needs to be explored in depth by future investigations to allow us to draw more
reliable conclusions. Another symptom domain that appears to be sensitive to the action of PUFAs is
that of self-harm conduct. The effects of PUFAs were studied in patients with a high risk of harmful
and suicidal behaviors, mainly in subjects with severe personality disorders, but also in patients
with mood disorders. Additional important factors that require evaluation in this population include
lipid-associated genetic variants and epigenetic markers that modulate the effects of lipid status and of
PUFAs supplementation on self-harm and suicide risk.
In conclusion, polyunsaturated fatty acids are dietary supplements that can have a role on the basis
of initial research data in treating several symptoms of psychiatric disorders, at least in combination
with traditional medications. The lack of severe adverse effects is a significant reason to carefully
consider the therapeutic potential of these agents. However, we have no sufficient evidence to draw
final conclusions and to propose official indications for PUFAs in psychiatry. This is mainly due to
serious limitations and considerable heterogeneity in the design and methods of available trials. As
is suggested by the organization of this review, the authors’ opinion is that less controversial and
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discordant data could be obtained in incoming studies by focusing, not on specific categorical diagnoses,
but on psychopathological dimensions and symptom domains observed from a trans-nosographical
perspective. Such dimensions could be the direct expression of the pathophysiological and biochemical
pathways on which PUFAs actually produce their beneficial effects.
Funding: This research was supported by the funds of the Italian Ministry of Health for the Departments
of Excellence.









FEP First episode of psychosis;
CDRS Childhood Depression Rating Scale;
CDI Childhood Depression Inventory;
EPDS Edinburgh Postnatal Depression Scale;
GDS Geriatric Depression Scale;
↓ Decrease of;
↑ Increase of;
MDD Major depressive disorder;
HDRS Hamilton Depression Rating Scale;
BDI Beck Depression Inventory;
PDSS Postpartum Depression Screening Scale;
PANSSPEP
Positive and Negative Syndrome ScaleIndividual-Family Psychoeducational
Psychotherapy;
BPD Borderline personality disorder;
PTSD Posttraumatic Stress Disorder;
PUFAs Polyunsaturated fatty acid;
> Superior of;
< Inferior of;
ADHD Attention Deficit Hyperactivity Disorder;
BDNF Brain-Derived Neurotrophic Factor
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